Keywords: Roche, OSI Pharma, Tarceva, ASCO, Lung cancer

Roche and OSI’s Tarceva shows impressive ability to stall lung cancer

Article | 06 June 2011

Print This

Swiss drug major Roche (ROG: SIX) and partner OSI Pharmaceuticals, now part of Japan’s Astellas (TYO: 4503), have presented ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in